|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
WednesdaySerono: REBIF...NEW FORMULA
REBIF: NEW FORMULA: "....less incidence of inflammation at the site of injections"..."formulation developed fewer antibodies -- immune system proteins that might attack the medicine -- a favorable finding that typically suggests a drug will work longer."
"The company said late-stage trials of the new formulation showed a "substantial improvement in overall tolerability... including less incidence of inflammation at the site of injections."Serono said the trials also showed that patients taking the new formulation developed fewer antibodies -- immune system proteins that might attack the medicine -- a favorable finding that typically suggests a drug will work longer." [more : Reuters] |